compounds to function as agonists. 2 In order to improve the antiproliferative properties of standard anti-androgens 3 and 4, and to possibly impede the receptor to adopt its closed agonist conformation in the presence of adaptive mutations, diverse new analogues were designed to increase the molecule occupational volume in proximity to the receptor helix 12, responsible for the closure movement to the agonist conformation, with the aim to impede this conformational change. Specifically, different hydrophobic aromatic substituents were explored with docking studies, and in particular attention was focused on fluorinated groups, in order to take advantage of the potential of fluorine to enhance the pharmacological properties and drug-like characteristics of compounds. 3 A 3,5-bis-trifluoromethyl group was identified as the best substituent for aromatic ring B of the parent structures to achieve this result (Figure 1) . The new analogues showed a marked improvement in in vitro antiproliferative activity on a range of human PC cell lines (VCap, LNCaP, DU-145 and 22Rv1), reaching sub-micromolar IC50 values. In addition, full AR antagonistic effect was observed for selected compounds and preclinical candidates were identified. A homology model of the human WT-AR open conformation was built using a single template approach in MOE2015. 4 The crystal structure of the progesterone receptor in its open antagonist form (PDB ID: 2OVM) was used as template (54% sequence identity with the human AR). 5 Docking of (R)-bicalutamide, enzalutamide and of the newly designed modifications was performed in the ligand binding domain (LBD) of the AR model using Plants docking software. 6 The predicted binding mode found for the parent compounds revealed the presence of free occupational space in the model structure in proximity to helix 12. As shown in Figure 2a , in silico studies suggest that the best substituent to fill this space is a 3,5-bis-trifluoromethyl group on aromatic ring B of the standard compounds. Due to the much bigger occupational volume in comparison with the 4-F substituent of bicalutamide, this 3 modification might impede the receptor closure even in the presence of adaptive mutations, such as the W741L mutation, the most common for bicalutamide. 7 As a further indication of this potential effect, docking of the newly designed compounds on the crystal structure of the complex bicalutamide-W741L AR (PDB ID 1Z95), which corresponds to the receptor closed conformation, reveals the presence of steric clashes between the new bis-trifluoromethyl portion of the molecule and helix 12
( Figure 2b) . Along with the insertion of a 3,5-bis-trifluoromethyl group in aromatic ring B of the parent structures, its replacement with a bulkier 3,5-di-tert-butyl substituent was also envisaged (compound 30f).
Moreover, ring A was explored as well for the repositioning and replacement of its original substituents with a bis-CF3 function. All planned modifications were carried out according to an optimised three or four-step synthetic pathway, adapted from literature procedures, [8] [9] [10] [11] [12] [13] [14] summarised in Schemes 1 and
Scheme 2.
Racemic bicalutamide derivatives, along with racemic bicalutamide, 10 were prepared by reacting methacryloyl chloride (5) Scheme 1 Synthetic pathways for the synthesis of racemic and R-bicalutamide analogues adapted from reported procedures. [8] [9] [10] [11] [12] Reagents and conditions: All newly synthesised compounds were evaluated for their antiproliferative effect in an in vitro 2D monolayer assay using four human prostate cancer cell lines ( Table 1 , absolute IC50 in µM). LNCaP, 5 VCaP and 22Rv1 cell lines exhibit some androgen sensitivity, whereas DU-145 is hormone-insensitive (Supporting Information, section S.3).
The activity of reference compounds 3 and 4 is consistent with previously reported data. [15] [16] [17] As recent research studies carried out in our group have shown the lack of significant difference in antiproliferative activity between racemic and R-bicalutamide analogues, 18 In the bicalutamide-derived series of analogues (compounds 24-42), all the newly synthesised compounds performed better than the standards in the antiproliferative assay, with the only exception being 37a, for which an antiproliferative effect could not be observed due to solubility issues. The besides the canonical anti-androgen mechanism. Nevertheless, the presence of an off-target can be speculated also for parent bicalutamide, for which the results obtained in our assay further confirm the previously reported lack of selectivity between LNCaP and DU-145 cell lines. 15 Due to this last consideration, and given the marked improvement in antiproliferative activity associated with the new structures, the presence of a potential off-target was not considered a limitation at this stage, while further investigations to assess the molecular mechanism underlying this effect will be the object of future studies.
As representative of the new series of compounds, 25a and 36a were evaluated for their antagonist/agonist effect on the AR using the GeneBLAzer® Betalactamase reporter technology for Nuclear receptors (NRs), to assess whether the antiproliferative activity found is correlated with any interference with the AR function. 19 Both compounds were found to be full antagonists of the androgen receptor in a single concentration antagonism experiment (10µM concentration, antagonistic effect > 80%), reducing the receptor activation induced by the standard agonist R1881. 20,21 A 10-concentration antagonism assay showed that 25a possess an antagonistic IC50 in the same range of (R)-bicalutamide and enzalutamide ( Table 2 ). The IC50 value found for (R)-bicalutamide is comparable with previously reported values in similar assays. Despite the fact that 36a shows a significantly improved antiproliferative effect, its action as AR antagonist seems to be reduced in terms of inhibitory IC50 in comparison with standard bicalutamide, thus indicating the presence of other aspects that contribute to its anti-prostate cancer properties, as already observed from the antiproliferative data. As a further confirmation of this potential off-target effect, additional in vitro studies on 36a and 41, our most active new analogue, were performed in order to evaluate their general cytotoxicity in comparison with 3, along with their metabolic stability ( The MTT cell viability assay was performed in a human hepatocarcinoma (HepG2) cell line, as a means to measure the effect of 36a and 41 on cell proliferation and other events that eventually lead to cell death. 24 Except for 51, the compounds analysed are characterised by an increased metabolic stability in comparison with standard bicalutamide. The tested analogues share a high affinity for human serum albumin, with values similar to the ones of R-bicalutamide found for all except 39e. Finally, none of 9 the compounds analysed showed any significant cardiotoxic effect (no IC50 could be evaluated). As a combination of its in vitro properties and antiproliferative profile in the four prostate-cancer cell lines, 42 has been chosen as pre-clinical candidate for the treatment of prostate cancer and will be evaluated in 22Rv1 prostate cancer mice models. In particular, 42 is one of the most active compounds identified in the antiproliferative assay, with an IC50 of 1.99 µM in the LNCaP cell-lines, the most active among the new sulfone derivatives. Being a sulfone this compound is also associated with the highest metabolic stability observed, and its plasma protein binding is highly similar to parent R-bicalutamide. 
